TY - JOUR
T1 - Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence
AU - Ishitobi, Makoto
AU - Okumura, Yasuhiro
AU - Arima, Nobuyuki
AU - Yoshida, Atsushi
AU - Nakatsukasa, Katsuhiko
AU - Iwase, Takuji
AU - Shien, Tadahiko
AU - Masuda, Norikazu
AU - Tanaka, Satoru
AU - Tanabe, Masahiko
AU - Tanaka, Takehiro
AU - Komoike, Yoshifumi
AU - Taguchi, Tetsuya
AU - Nishimura, Reiki
AU - Inaji, Hideo
N1 - Funding Information:
ACKNOWLEDGMENT This study was supported in part by Grants-in-aid for scientific research from the Japanese Breast Cancer Society.
PY - 2013/6
Y1 - 2013/6
N2 - Background: There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR). Methods: One hundred eighty-five patients were classified according to breast cancer subtype, as approximated by estrogen receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67, of IBTR, and we evaluated whether breast cancer subtype was associated with distant recurrence after IBTR. Results: There was a significant difference in distant disease-free survival (DDFS) after IBTR according to breast cancer subtype defined by a cutoff of the Ki-67 index of 20 % (p = 0.0074, log-rank test). The 5-year DDFS rates for patients with luminal A, luminal B, triple-negative, and HER2 types were 86.3, 57.1, 56.6, and 65.9 %, respectively. In addition, breast cancer subtype was significantly associated with distant recurrence after IBTR on adjustment for various clinicopathologic factors (p = 0.0027, Cox proportional hazards model). Conclusions: Our study suggests that breast cancer subtype based on immunohistochemical staining predicts the outcomes of patients with IBTR. Further analyses are needed (UMIN-CTR number UMIN000008136).
AB - Background: There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR). Methods: One hundred eighty-five patients were classified according to breast cancer subtype, as approximated by estrogen receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67, of IBTR, and we evaluated whether breast cancer subtype was associated with distant recurrence after IBTR. Results: There was a significant difference in distant disease-free survival (DDFS) after IBTR according to breast cancer subtype defined by a cutoff of the Ki-67 index of 20 % (p = 0.0074, log-rank test). The 5-year DDFS rates for patients with luminal A, luminal B, triple-negative, and HER2 types were 86.3, 57.1, 56.6, and 65.9 %, respectively. In addition, breast cancer subtype was significantly associated with distant recurrence after IBTR on adjustment for various clinicopathologic factors (p = 0.0027, Cox proportional hazards model). Conclusions: Our study suggests that breast cancer subtype based on immunohistochemical staining predicts the outcomes of patients with IBTR. Further analyses are needed (UMIN-CTR number UMIN000008136).
UR - http://www.scopus.com/inward/record.url?scp=84878232748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878232748&partnerID=8YFLogxK
U2 - 10.1245/s10434-012-2825-1
DO - 10.1245/s10434-012-2825-1
M3 - Article
C2 - 23292516
AN - SCOPUS:84878232748
SN - 1068-9265
VL - 20
SP - 1886
EP - 1892
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -
